Oliver De Henau

Title: Oliver De Henau: Innovator in Pharmaceutical Composition

Introduction

Oliver De Henau is a notable inventor based in Watermaele-Boitsfort, Belgium. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative compounds that target cancer treatment.

Latest Patents

Oliver De Henau holds a patent for "Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents." This invention relates to thiocarbamate derivatives of Formula (I), which serve as A2A adenosine receptor (A2AR) inhibitors. The pharmaceutical composition includes an A2A inhibitor of Formula (I) combined with lipid carriers such as lauroyl macrogol-32 glycerides or D-α-tocopherol-polyethylene glycol-1000 succinate. This composition is particularly effective for oral dosing in cancer treatment. Additionally, the invention encompasses combinations of the A2A receptor inhibitor with anticancer agents, including immunotherapeutic agents like checkpoint inhibitors.

Career Highlights

Oliver De Henau is currently associated with Iteos Belgium SA, where he continues to advance his research and development efforts in the pharmaceutical sector. His work focuses on creating effective treatments for cancer, leveraging his expertise in medicinal chemistry.

Collaborations

Oliver collaborates with esteemed colleagues such as Stefano Crosignani and Erica Joke Katelijne Heleen Houthuys. These partnerships enhance the innovative potential of his research and contribute to the advancement of cancer therapies.

Conclusion

Oliver De Henau is a prominent figure in the pharmaceutical industry, recognized for his innovative work in cancer treatment. His patent on thiocarbamate derivatives showcases his commitment to developing effective therapeutic solutions.